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SHORT REPORT Open Access
Aging-associated increase in indoleamine 2,3-
dioxygenase (IDO) activity appears to be unrelated
to the transcription of the IDO1 or IDO2 genes in
peripheral blood mononuclear cells
Saara Marttila1*, Juulia Jylhävä1, Carita Eklund1, Antti Hervonen2, Marja Jylhä2 and Mikko Hurme1,3
Abstract
Background: Old age is associated with increased levels of circulating pro-inflammatory cytokines, a phenomenon
termed inflamm-aging. Elevated levels of pro-inflammatory cytokines have been associated with several age-
associated diseases and with a shortened lifespan. Indoleamine 2,3-dioxygenase (IDO) has immunomodulatory
properties and its activity is elevated in inflammation, autoimmune disorders and malignancies. We have previously
shown that IDO activity is increased in nonagenarians compared to young individuals and that high IDO activity is
associated with mortality at old age.
Findings: In this study our aim was to assess whether this difference in IDO activity in the plasma was due to the
differential expression of either the IDO1 or IDO2 gene in peripheral blood mononuclear cells. Our results show
that IDO1 and IDO2 are not differently expressed in nonagenarians compared to controls and that the expression
of IDO genes is not associated with the level of IDO activity in the plasma.
Conclusion: The level of IDO activity in the plasma is not regulated through the expression of IDO1 or IDO2 in the
peripheral blood mononuclear cells.
Findings
The aging-associated decline of the immune system,
termed immunosenescence, is characterized by aber-
rantly functioning T cell populations and an increased
level of circulating pro-inflammatory cytokines
(inflamm-aging). The levels of CRP, IL-6, TNF-a,
among others, are increased in the blood of aged indivi-
duals and this increase is associated with a shortened
lifespan [1,2]. The high levels of pro-inflammatory cyto-
kines are also associated with several age-related condi-
tions such as dementia, Parkinson’s disease,
atherosclerosis, type 2 diabetes, sarcopenia and func-
tional disability. An age-associated increase in the pro-
duction of TNF-a, IL-6 and IL-1Ra has been reported
in unstimulated peripheral blood mononuclear cells
(PBMCs). However, other cell types, such as endothelial,
adipose and macrophage-derived cells, probably also
contribute to the plasma levels of these and other pro-
inflammatory cytokines. The inducers of these molecules
and the mechanisms of activation of the genes asso-
ciated with them remain poorly characterized [1,2].
Indoleamine 2,3-dioxygenase is an immunomodulatory
enzyme, the activity of which is elevated in several
inflammatory conditions, such as infection, autoimmune
disorders and malignancies [3]. The IDO enzyme is the
first and also the rate-limiting enzyme in the pathway
that converts tryptophan (trp) to kynurenine (kyn). IDO
can suppress effector T cells and stimulate the differen-
tiation of naïve T cells to regulatory T cells (Tregs). The
levels of IDO are elevated when the immune reaction is
polarized towards the Th1 response, but there is also
evidence of a negative feed-back loop, where high IDO
levels down regulate the Th1 response and stimulate a
Th2 response [4,5].
There are two genes encoding IDO enzyme, IDO1 and
IDO2. IDO1 is expressed intracellularly in the placenta,
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lung, small intestine, colon, spleen, liver, kidney, sto-
mach and brain. Cell types that express IDO1 include
myeloid-lineage cells (dendritic cells, monocytes, macro-
phages and eosinophils), epithelial cells, fibroblasts, vas-
cular smooth muscle cells, endothelial cells and certain
tumor cell lines. The main inducer of IDO1 both in
vitro and in vivo is type II interferon (IFN-g), but it can
also be induced by IFN-a, IFN-b and lipopolysaccharide
(LPS). Other factors can also modulate IDO1 expression
depending on the cell type [6]. IDO2 was only recently
found, and its biological role is still unclear. In humans
IDO2 mRNA is expressed in the liver, small intestine,
spleen, placenta, thymus, lung, brain, kidney and colon
[7]. It appears that the enzyme produced by IDO2 can
catabolize the same substrates as IDO1 but with lower
efficiency [8]. Mouse studies show that when IDO1 and
IDO2 are expressed in the same tissue, they are
expressed in different cell types, suggesting that there is
no functional redundancy between the two enzymes [9].
The hepatic enzyme tryptophan 2,3-dioxygenase (TDO)
also catalyzes the same reaction as IDO, but there are
no indications that it is regulated by inflammatory cyto-
kines. However, as aging affects the majority of organ
systems, the contribution of TDO to the elevated degra-
dation of trp cannot be completely excluded.
The ratio of first metabolite, kyn, to the substrate, trp,
can be used as an indicator of IDO activity in circum-
stances related with concomitant immune activation.
Increased degradation of trp has been associated with
elevated levels of inflammation markers, such as neop-
terin and IFN-ɣ, in HIV infection, sepsis, autoimmune
disorders and malignancies [3]. The same phenomenon
is seen also in the elderly population, in which increased
degradation of trp is associated with increased produc-
tion of homocysteine and neopterin [10].
The association of inflammation and IDO activity in
the plasma has been shown in various studies, but the
majority of these studies did not identify the cell type
producing the IDO enzyme. However, in untreated HIV
infection the level of trp degradation i.e. IDO activity
has been shown to be elevated [11,12] and Boasso et al.
have shown that the level of IDO mRNA expression in
the PBMCs has also increased [13].
We have shown that the activity of IDO in the plasma,
as determined by the ratio of the main metabolite to
substrate, kyn to trp, is increased in nonagenarians com-
pared to young individuals, and that the high IDO activ-
ity is associated with a shortened lifespan in
nonagenarians during a four-year follow-up [14]. In this
study our aim was to assess whether the difference of
IDO activity in the plasma was due to the differential
expression of either IDO1 or IDO2 in peripheral blood
mononuclear cells. This is the first study assessing the
relationship of IDO expression and IDO activity in a
non-stimulated and non-acute situation.
The study population consisted of 12 healthy women
(nonagenarians, n = 8 and controls, aged 25-37, n = 4).
The nonagenarian women represented the best-func-
tioning respondents to the mailed Vitality 90+ survey.
For original cohort description, see [15]. The blood sam-
ples were drawn by a home-visiting nurse into EDTA
collection tubes and were directly subjected to leukocyte
separation with Histopaque 1077 density gradient (His-
topaque®-1077, cat. no. 10771, Sigma-Aldrich, MO,
USA). The plasma layer was collected and stored at -20°
C. The PBMC layer was collected, and the cells were
suspended into 1 ml of RPMI-160 medium (cat. no.
Figure 1 IDO enzyme activity in nonagenarians and young
controls. The ratio of kyn to trp, indicating IDO enzyme activity, is
elevated in the plasma of nonagenarians compared to young
controls (p = 0.011, Mann-Whitney U-test).
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R0883, Sigma-Aldrich, MO, USA). Immediately after the
PBMC separation, traces of erythrocytes were lysed with
a 10-second H2O treatment and immediately recovered
with 0.9% NaCl. Plasma concentrations of trp (mmol/L)
and kyn (μmol/L) were measured with high-perfor-
mance liquid chromatography as described previously
[16]. Briefly, samples were deproteinized with nitrotyro-
sine containing TCA-buffer. Samples were mixed
troughoutly and incubated at +4°C for 15 minutes, after
which they were centrifuged twice with 10000 × g for
15 and 6 minutes. The clear supernatant was used for
the analysis. Trp was separated with a Shimadzu liquid
chromatograph LC-10AD VP (Shimadzu Co, Kyoto,
Japan) using a 50-mm DS HypersilC18 5 μm column
(Thermo Electron Co, Bellefonte, PA, USA) and was
monitored with a Shimadzu RF-10A XL detector at 266
nm excitation and 366 nm emission wavelengths. Kyn
was separated with a Hewlett-Packard 1100 liquid chro-
matograph (Palo Alto, CA, USA) using LiChroCart 55-
4150 mm cartridge containing a Purospher STAR RP-18
3 μm column (Merck Co, Darmstadt, Germany) and
was analyzed at 360 nm wavelengths with a Hewlett-
Packard G13144 detector. Total RNA extraction from
PBMCs was performed with the Qiagen RNeasy® Midi
kit (cat. no. 75144, Qiagen, CA, USA) according to the
manufacturer’s instructions. Levels of IDO1 and IDO2
transcripts in the PBMCs were determined with Taq-
Man real-time PCR using separate gene expression
assays (Hs00158027_m1 for IDO1 and Hs00401201_m1
for IDO2, Applied Biosystems, CA, USA). To determine
whether IDO1 or IDO2 are expressed differently
between the nonagenarians and the control population,
we calculated the RQ value for those genes. This was
done with Relative Quantification (RQ) documents and
the RQ Manager Software (Applied Biosystems, CA,
USA).
As in our previous work [14], there was a significant
difference in the IDO activity in the plasma between the
nonagenarians and the young controls; the level of IDO
activity is higher in the plasma of the nonagenarians
compared to young controls (Figure 1). However, the
data obtained showed that there was no difference in
the expression levels of IDO1 and IDO2 in nonagenar-
ians compared to young controls (Table 1). Neither did
the level of IDO1 or IDO2 expression in PBMCs corre-
late with the IDO activity in the plasma in nonagenar-
ians or in young controls (Figure 2).
Our data indicates that the level of IDO enzyme activ-
ity in the plasma is not produced by the expression of
IDO1 or IDO2 in PBMCs. PBMCs isolated by density
centrifugation consist mainly of T cells, the proportion
of monocytes, macrophages and dendritic cells is smal-
ler. However, the latter cell types might be more impor-
tant for IDO activity. Boasso et al. [13] showed that only
3% of PBMCs express IDO, majority of these were plas-
macytoid dendritic cells. However, the difference in IDO
mRNA expression observed in their study between
patients and controls was seen in uncharacterized
PBMCs. Thus if the difference in IDO activity in the
plasma was produced even by a small subpopulation of
PBMCs, the difference in IDO1 or IDO2 gene
Table 1 The expression levels of IDO1 and IDO2 in
PBMCs.
ΔCt Controls ΔCt Nonagenarians RQ p
IDO1 4.82 5.05 0.85 n.s.
IDO2 9.17 9.75 0.67 n.s.
No statistically significant differences were found in the expression levels of
IDO1 or IDO2 in PBMCs between nonagenarians and young controls, despite
the difference in the level of IDO enzyme activity in the plasma.
Figure 2 IDO activity and expression. The level of IDO enzyme activity in the plasma does not correlate with the level of IDO1 or IDO2
expression in PBMCs in the whole population (Spearman’s rho -0.503, p = 0.095; rho = 0.077 p = 0.812, respectively), nor in the nonagenarians
or young controls separately.
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expression should have been detected also in our sample
of uncharacterized PBMCs.
The high concentrations of kyn compared to trp in
the plasma of nonagenarians probably is a result of IDO
expression in other cells and tissues aside from PBMCs.
Local IDO activity has been shown to affect systemic trp
concentrations, at least in malignancies [17]. One strong
candidate for the source of IDO activity in the plasma is
the IDO expression in the endothelial cells of blood ves-
sels [18,19]. It is also possible that the level of IDO
activity is regulated through the posttranslational modi-
fications that are needed for an active IDO enzyme, for
example, the binding of heme [20]. It is of interest
whether the elevation of IDO activity observed in differ-
ent inflammatory states is brought about by different
cell types depending on the case, especially if there is a
difference between inflamm-aging and other inflamma-
tory states.
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